Cost-effectiveness of follow-up invasive coronary angiography after percutaneous coronary stenting: a real-world observational cohort study in Japan

Conclusions FUICA increased the costs but did not improve clinical benefits. Thus, FUICA is not economically more attractive than CF alone. Trial registration number UMIN000039768.
Source: BMJ Open - Category: General Medicine Authors: Tags: Open access, Health economics Source Type: research